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symptomatic pseudo-progression after SRT of brain 
metastases needs to be considered as a serious radiation 
induced toxicity. Reduction of the high dose volume of 
normal brain tissue may prevent this toxicity. 
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Purpose or Objective: Following EBRT for prostate cancer, 
patients can develop aggravation of urinary symptoms mostly 
due to urethral dose. With dose-escalated EBRT it is 
suggested that genitourinary toxicity increases with 
increasing dose. In the experimental arm of the FLAME-trial 
(284 patients) a dose of 77Gy to the entire prostate gland in 
35 fractions was administered, with an integrated boost up to 
95Gy to the macroscopic lesions. No dose constraints for the 
urethra were set during the trial. The objective of this study 
is to evaluate urethral dose parameters, urethra-related 
toxicity and prostate-specific QoL scores for patients treated 
with and without dose-escalated EBRT.  
 
Material and Methods: Between 2009 and 2015, 571 
intermediate and high risk prostate cancer patients were 
enrolled in the FLAME trial, a phase 3, single blind, multi-
center randomized controlled trial (NCT01168479). The 
control arm (287 patients) received a dose of 77Gy to the 
entire prostate gland in 35 fractions. The experimental arm 
(284 patients) received the same dose, but with an 
integrated boost up to 95Gy to the multi-parametric MRI-
based intraprostatic lesion. For this study, the urethra was 
delineated retrospectively on T2 weighted MRI, using a circle 
shape with a diameter of 3 mm, to obtain dose parameters. 
These dose parameters, the Genitourinary Toxicity 
scores(CTCAE v3.0) and the urinary symptoms scale of the 
EORTC QLQ-PR25, were compared for both treatment arms. 
The physician in attendance scored toxicity at baseline, 
weekly during treatment, 4 weeks after treatment and every 
6 months up to 10 years. QoL was filled out 1 week before 
treatment and the next questionnaires were sent to the 
patient every 6 months up to 10 years. Mean differences 
between groups at 1 year of follow-up were calculated using 
an independent samples t-test (dosimetry and QoL), Chi-
square test or Fisher’s exact test (toxicity). Statistical 
significance was considered P<0.01.  
 
Results: Results after analysis of 100 patients (50 patients in 
each treatment arm) with a median follow-up of 22 months 
show for the control arm an average Dmean (mean dose to 
the urethra) of 77.3 ± 0.5 Gy (range 75.9-78.0 Gy), with an 
average Dmax (maximum dose to the urethra) of 79.6 ± 0.8 
Gy (range 78.0-81.3). In the experimental arm, average 
Dmean was 82.0 ± 2.8 Gy (range 77.4-89.0 Gy) and average 
Dmax was 89.7 ± 0.6 Gy (range 80.7-97.7 Gy). For both 
Dmean and Dmax the difference between treatment arms 
was significant (p=0.000). Grade 3 GU toxicity did not occur, 
grade 2 GU toxicity occurred in a subset of patients, although 
no significant difference was found between both treatment 
arms for the separate GU items (table 1). Urinary symptoms-
related QOL was not significantly different across treatment 
arms. 
 
 
Conclusion: Results showed a significant difference in 
urethral dose, but no significant differences in toxicity or 
quality of life when comparing both treatment arms of the 
FLAME trial. 
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Purpose or Objective: Radiotherapy of lung cancer delivers 
quite high doses of radiation to the heart. We explored 
associations between overall survival (OS) and radiation dose 
to heart and its substructures and electrocardiographic (ECG) 
changes. 
 
Material and Methods: We analysed data from 79 patients in 
IDEAL CRT, a phase I/II trial of isotoxic radiotherapy (RT) 
dose escalation trial, sponsored by University College London 
(C13530/A10424). Mean and maximum prescribed doses were 
69 and 75.6Gy calculated as 2Gy fractionation equivalents 
(EQD2, α/β=10Gy). Whole heart, left ventricle (LV), right 
ventricle (RV), right atrium (RA), left atrium (LA) and AV 
node (AVN) were outlined on RT planning scans and 
differential dose volume histograms (DVHs) extracted, 
converting physical DVHs to EQD2s (α/β=3). Patient-to-
patient DVH variability was represented using a small number 
of Varimax-rotated principal components (PCs) explaining 
95% of total variance. ECGs were analysed at baseline, 6 and 
12 months (mo) after treatment, and changes in heart rate 
(HR) recorded, with patients dichotomised according to 
presence or absence of ‘any ECG rhythm change’ (conduction 
abnormalities or ischaemia). OS was modelled using Cox 
regression from the start of treatment. Univariate analysis 
(UVA) and multivariate analysis (MVA) of clinical factors 
included ‘any rhythm ECG change’ at 6 and 12 months, 
change in HR at 6 or 12 months, planning target volume 
(PTV), and prescribed dose (PD). MVA of whole heart 
dosimetric factors included all 7 Heart PCs, PTV, and PD. MVA 
of heart substructures included heart substructure PCs with p 
< 0.2 on UVA having similar dosimetric distributions to 
significant Heart PCs, PTV and PD. 
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Results: ECGs at baseline and 6 mo were available for 54 
patients, and at baseline and 12 mo for 49 patients. At 6 mo 
and 12 mo, 10 and 6 patients had ischemic changes and 12 
and 15 patients had conduction abnormalities (AF or sinus 
tachycardia). Median PTV was 403.4cm3 (Range 138.7-
1262.1). Larger PTV and ‘any ECG rhythm change’ at 6 mo 
were associated with worse OS (HR = 1.005, 95% CI: 1 - 1.01 p 
0.04; HR = 7.9843, 95% CI: 1.293 - 47.583 p 0.03 respectively) 
on MVA. Increasing values of Heart PC2, Heart PC3 and Heart 
PC7 (characterizing heart volume (vol) receiving 10-30Gy plus 
70-80Gy, 65-75Gy and 1-5Gy respectively) were associated 
with worse OS (HR = 0.844, 95% CI: 0.715– 0.995 p 0.04; HR = 
1.238, 95% CI: 1.051 - 1.457 p 0.01; HR = 1.725, 95% CI: 1.006 
- 2.958, p 0.05 respectively) on MVA. Increasing values of LA 
PC4 (LA vol receiving 65-75Gy) was associated with worse OS 
on MVA (HR = 1.129, 95% CI: 1.033 - 1.235 p <0.01). 
 
 
Conclusion: We found evidence of a possible association 
between lower OS in IDEAL-CRT patients and high PTV, 
ischaemic or conduction change on ECG at 6 mo, and 
relatively high heart volume receiving doses <5Gy, 10-30Gy, 
65-75Gy and 70-80Gy with the 65-75Gy localising to LA. 
Further prospective studies are required to improve 
understanding of cardiac irradiation in NSCLC. 
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Purpose or Objective: Breast cancer patients with 
cardiovascular risk factors are at increased risk of radiation- 
and chemotherapy- induced cardiovascular complications. 
Presence of coronary artery calcifications (CAC) is a major 
independent risk factor for cardiovascular disease (CVD). This 
study investigates the prevalence of CAC in breast cancer 
patients on radiotherapy (RT) planning CT scans, and its 
association with cardiovascular risk factors. 
 
Material and Methods: This study was conducted within the 
Utrecht cohort for Multiple BReast cancer intErvention 
studies and Long-term evaLuAtion (UMBRELLA), and includes 
561 breast cancer patients undergoing planning CT scans at 
the UMC Utrecht between October 2013-March 2015. CAC was 
automatically scored using a validated algorithm that 
identifies CAC with a supervised pattern and threshold of 130 
Hounsfield Units. Patients were categorized according to CAC 
(Agatston) scores: 0, 1-10, 11-100, 101-400, >400.  
Cardiovascular risk factors (diabetes, smoking status, 
hypercholesterolemia, hypertension, history of CVD) were 
collected for 36 patients with intermediate to high CVD risk 
(scores>100), and for a random selection of patients with fair 
to moderate CVD risk (1≤ scores ≤100, n=36) and low CVD risk 
(without CAC, i.e. scores of 0, n=36). Demographic, disease 
characteristics, and presence of cardiovascular risk factors 
were compared between groups using Chi-square analysis and 
Kruskal-Wallis test for categorical and continuous data 
respectively. 
 
Results: Median age of the cohort was 58 years (range: 26-
85). There were 427 (76%) patients without CAC, 50 (9%) with 
scores between 1-10, 43 (7%) with scores between 11-100, 
and 36 (7%) patients with scores >100. Patients with scores 
>100 had significantly more often diabetes than those 
without CAC (28% vs. 3%, p<0.001). Patients with scores >100 
had more often three to four CVD risk factors compared to 
patients with scores between 1-100 or without CAC: 30%, 5%, 
0% respectively, p=0.002. Ten (28%) patients with scores >100 
did not have any other CVD risk factor  
 
Conclusion: CAC is present in one in four breast cancer 
patients. In one third of patients with CAC scores >100, no 
other CVD risk factors were present, and these patients 
would not have been identified as high risk using standard 
CVD risk factors. Since CAC can be automatically detected 
without additional cost or radiation exposure in breast cancer 
patients undergoing RT, it represents a simple and useful way 
to detect those requiring additional cardio protective 
measures. 
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Purpose or Objective: Cardiovascular diseases are 
increasingly recognized as late effects of Hodgkin lymphoma 
(HL) treatment. Radiation therapy is known to contribute to 
the risk of heart failure (HF), but a dose-response 
relationship has yet not been well described. The purpose of 
this study was to identify risk factors for HF, and to quantify 
effects of radiation dose to the heart, chemotherapy, and 
other cardiovascular risk factors. 
 
Material and Methods: We conducted a nested case-control 
study in a cohort of 2,617 5-year HL survivors, treated 
between 1965-1995. Cases were patients who developed HF 
in the form of either symptomatic congestive heart failure or 
cardiomyopathy (Common Terminology Criteria for Adverse 
Events version 4.0: grade ≥2) as their first clinically 
significant heart disease. Detailed treatment information was 
collected from medical records of 91 cases and 278 matched 
controls. Mean heart dose (MHD) was retrospectively 
estimated by reconstruction of individual treatments on 
representative computed tomography datasets. All statistical 
tests were two-sided. 
 
